128 related articles for article (PubMed ID: 276342)
1. The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
Nixon PF
Aust N Z J Surg; 1978 Feb; 48(1):17-21. PubMed ID: 276342
[TBL] [Abstract][Full Text] [Related]
2. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
[TBL] [Abstract][Full Text] [Related]
3. 5-S-cysteinyldopa in the urine of melanoma patients.
Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
[TBL] [Abstract][Full Text] [Related]
4. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
Paul E; Graef V; Ruppel R; Hellwich M
Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
[TBL] [Abstract][Full Text] [Related]
5. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
Paul E; Graef V; Ruppel R
Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
[TBL] [Abstract][Full Text] [Related]
7. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
Graef V; Paul E
Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
[TBL] [Abstract][Full Text] [Related]
8. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
Ichihasi M; Mojamdar M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
[No Abstract] [Full Text] [Related]
9. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
[TBL] [Abstract][Full Text] [Related]
10. [Melanoma metabolites (proceedings)].
Rorsman H
Lakartidningen; 1978 Dec; 75(49):4596-7. PubMed ID: 723347
[No Abstract] [Full Text] [Related]
11. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
Beyer C; Fiedler H; Wohlrab W; Wozniak KD
Dermatol Monatsschr; 1986; 172(9):541-4. PubMed ID: 3098590
[No Abstract] [Full Text] [Related]
12. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
Mojamdar M; Ichihashi M; Mishima Y
J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
[No Abstract] [Full Text] [Related]
13. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
Inoi T; Mojamdar M; Ichihashi M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1982 Sep; 92(10):1065-9. PubMed ID: 6821170
[No Abstract] [Full Text] [Related]
14. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Stewart RM; Miller S; Gunder M
Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
Agrup G; Hafström L; Jönsson PE; Rorsman H
Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
[No Abstract] [Full Text] [Related]
16. Trichochromes in the urine of melanoma patients.
Agrup G; Lindbladh C; Prota G; Rorsman H; Rosengren AM; Rosengren E
J Invest Dermatol; 1978 Feb; 70(2):90-1. PubMed ID: 621413
[TBL] [Abstract][Full Text] [Related]
17. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
Marnot D; Decaux F; Berthelot P; Kalis B; Jardillier JC; Warren L
Cancer Detect Prev; 1983; 6(1-2):303-10. PubMed ID: 6411338
[TBL] [Abstract][Full Text] [Related]
18. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T
Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132
[TBL] [Abstract][Full Text] [Related]
20. Isolation of 2-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa from the urine of patients with melanoma.
Prota G; Rorsman H; Rosengren AM; Rosengren E
Experientia; 1977 Jun; 33(6):720-1. PubMed ID: 891724
[No Abstract] [Full Text] [Related]
[Next] [New Search]
